Brian B Hughley1, Steven M Sperry2, Timothy A Thomsen3, Mary E Charlton4, Nitin A Pagedar2. 1. Department of Otolaryngology - Head and Neck Surgery, University of Alabama - Birmingham, Birmingham, Alabama. 2. Department of Otolaryngology - Head and Neck Surgery, University of Iowa, Iowa City, Iowa. 3. Department of Internal Medicine - Palliative Care Program, University of Iowa, Iowa City, Iowa. 4. Department of Epidemiology, University of Iowa, Iowa City, Iowa.
Abstract
BACKGROUND: This study is an evaluation of survival in patients with upper aerodigestive tract (UADT) cancer who did not receive guideline-directed therapy. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was examined to identify patients with invasive cancer of the UADT. Patients were classified as "untreated" if they received neither surgery nor radiotherapy. Kaplan-Meier observed survival estimates were computed and stage-specific actuarial estimates of relative survival were computed. RESULTS: Of 3589 untreated patients, 13.7% were black, compared to 9.5% white, and 9.2% all other races (p <.0001). Patients with stage IV disease were more likely to be untreated than those with stage I disease (11.9% vs 3.8%; p <.0001). Median survival was 39 months for treated patients and 4 months for untreated patients. CONCLUSION: The median survival for untreated patients was 4 months. Stage, race, and primary site were independently associated with untreated status.
BACKGROUND: This study is an evaluation of survival in patients with upper aerodigestive tract (UADT) cancer who did not receive guideline-directed therapy. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was examined to identify patients with invasive cancer of the UADT. Patients were classified as "untreated" if they received neither surgery nor radiotherapy. Kaplan-Meier observed survival estimates were computed and stage-specific actuarial estimates of relative survival were computed. RESULTS: Of 3589 untreated patients, 13.7% were black, compared to 9.5% white, and 9.2% all other races (p <.0001). Patients with stage IV disease were more likely to be untreated than those with stage I disease (11.9% vs 3.8%; p <.0001). Median survival was 39 months for treated patients and 4 months for untreated patients. CONCLUSION: The median survival for untreated patients was 4 months. Stage, race, and primary site were independently associated with untreated status.
Authors: Daniel J Givens; Lucy Hynds Karnell; Anjali K Gupta; Gerald H Clamon; Nitin A Pagedar; Kristi E Chang; Douglas J Van Daele; Gerry F Funk Journal: Arch Otolaryngol Head Neck Surg Date: 2009-12
Authors: D Pope; H Ramesh; R Gennari; G Corsini; M Maffezzini; H J Hoekstra; D Mobarak; K Sunouchi; A Stotter; C West; R A Audisio Journal: Surg Oncol Date: 2006-12 Impact factor: 3.279
Authors: S G Patel; M Amit; T C Yen; C T Liao; P Chaturvedi; J P Agarwal; L P Kowalski; A Ebrahimi; J R Clark; C R Cernea; S J Brandao; M Kreppel; J Zöller; D Fliss; E Fridman; G Bachar; T Shpitzer; V A Bolzoni; P R Patel; S Jonnalagadda; K T Robbins; J P Shah; Z Gil Journal: Br J Cancer Date: 2013-09-24 Impact factor: 7.640
Authors: Catriona R Mayland; Kate Ingarfield; Simon N Rogers; Paola Dey; Steven Thomas; Andrea Waylen; Sam D Leary; Miranda Pring; Katrina Hurley; Tim Waterboer; Michael Pawlita; Andy R Ness Journal: Palliat Med Date: 2020-02-27 Impact factor: 4.762
Authors: Axel Sahovaler; Tommaso Gualtieri; David Palma; Kevin Fung; S Danielle MacNeil; John Yoo; Anthony Nichols Journal: Acta Otorhinolaryngol Ital Date: 2021-02 Impact factor: 2.124